We support and invest in early stage, life science initiatives that share our vision.
We accelerate healthcare innovation through investment and partnerships. Because we believe data science has the potential to transform patient care, we are investing in early stage initiatives that share our vision.
Why Partner with us?
BioInfoGate understands investment as a collaborative partnership. We help nurture strategic projects by providing valuable in-kind resources and hands-on support.
- Industry expertise in data and the life sciences
- Network and connections in data science ecosystem
- Opportunity to cross-fertilize ideas
- Hands-on support from BioInfoGate team
- Long-term commitment
- Access to mentors and advisors
In sum, we appreciate and understand how much effort goes into starting a successful data driven company in the life sciences. If you are developing innovative intellectual property assets in the field of data science applied to therapeutic discovery, we want to hear from you.
We are looking for early stage startups, academic research teams or companies with novel uses of data in the life sciences. Our goal is to help promising research projects reach proof of concept and move their work from bench to bedside.
Areas of Interest
- Big Data in Life Sciences
- Analytics & Visualization
- Synthetic Biology
- Medical Technology
- Digital Health
Priority Therapeutic Areas
Our Investment Criteria
- Early Stage Proof of Concept
- New Therapeutic Targets
- Clear and Scalable Business Model
- Data Science Talent
- Data Science Approach
Texto a definir
Our Portfolio - Investments
Orphan therapies for vision impairment: optic neuritis and neuromyelitis optica. Bionure is developing first-in-class SGK agonists for the treatment of rare, ophthalmological diseases which currently have no available treatment options.
State of the art imaging solutions using advanced computational models on radiological images for early diagnosis, lesion grading-phenotyping-staging, treatment selection/follow-up and validation against clinical endpoints.